Undisclosed Lead Program

About ImmunSYS

ImmunSYS is a private, preclinical-stage biotech developing biologics for autoimmune and inflammatory disorders. Operating from the San Diego biotech hub, the company is building a pipeline based on a proprietary platform targeting immune dysregulation. As a pre-revenue entity, its success hinges on advancing its lead candidates into clinical trials and securing strategic partnerships or further investment. The company operates in a high-potential but intensely competitive therapeutic area.

About Humanity Neurotech

Founded in 2019, Humanity Neurotech is a pre-revenue, private biotech firm targeting the large and growing market for mental health and cognitive therapeutics. The company is developing a neurotechnology platform, likely involving non-invasive neuromodulation, software-based interventions, or a combination thereof, to create novel digital treatments. As an early-stage venture, its success hinges on clinical validation, regulatory strategy, and securing continued funding to advance its pipeline. The company operates in a competitive but high-potential sector driven by increasing mental health needs and the digitization of healthcare.

About Mirror Biologics

Founded in 2018 and based in San Diego, Mirror Biologics is a private, pre-clinical stage biotech focused on autoimmune and inflammatory conditions. The company's core strategy revolves around its proprietary antibody engineering technology to design next-generation biologics. As a typical early-stage biotech, it is pre-revenue and likely funded by venture capital. Its success hinges on advancing its platform and pipeline candidates into clinical development to address significant unmet medical needs.

About XenImmune Therapeutics

XenImmune Therapeutics is a private, preclinical-stage biotech developing a novel therapeutic platform inspired by transplant rejection biology. The company's technology uses antibody-enzyme fusion proteins to coat solid tumors with foreign sugar antigens, thereby triggering a potent, innate immune attack against the cancer. This approach aims to overcome tumor immune evasion and has demonstrated initial proof-of-concept in vitro and in vivo. The modular platform is designed to be adaptable across multiple solid tumor types with high unmet need.

About Rhythio Medical

Rhythio Medical is an early-stage, pre-revenue medical device innovator targeting the large and growing cardiovascular implant market. With a focus on implantable devices for rhythm management and heart failure, the company is likely developing next-generation pacemakers, defibrillators, or cardiac resynchronization therapy (CRT) devices, though specific technology details are not publicly disclosed. As a young, private company, its success will depend on securing venture funding, advancing through preclinical and clinical testing, and navigating a competitive landscape dominated by large, established players like Medtronic, Abbott, and Boston Scientific.

About Radella Pharmaceuticals

Radella Pharmaceuticals is a private, pre-clinical-stage biotech developing a novel mechanism of action (MOA) targeting a protein-protein interaction involved in insulin sensitivity and energy expenditure. This approach, distinct from current incretin-based therapies for diabetes and obesity, aims to be disease-modifying and has shown promise in non-clinical models for improving metabolic function. The company plans to initiate human clinical trials in early 2024, initially targeting cardiometabolic diseases with potential expansion into atherosclerosis, dementia, and fatty liver disease. Backed by a leadership team with strong endocrinology and metabolic disease expertise, Radella is privately funded through proof-of-concept studies.

Therapeutic Areas